Cambridge Innovation Capital Plc, a venture capital company supporting businesses in and around Cambridge, UK has raised £150 million in new capital to support its portfolio of healthcare and technology companies. The financing is one of the largest private rounds in Europe this year and more than doubles to £275 million the resources available to the company.
Novartis is to spend $310 million upfront to acquire a portfolio of candidate small molecule drugs targeting a pathway in the innate immune system that could potentially treat chronic inflammatory disorders as well as nonalcoholic steatohepatitis (NASH), a condition in which fat builds up in the liver.
Evotec AG continued to benefit in 2018 from its dual business model as a service provider and drug discoverer and developer, delivering a 42% increase in revenue to €375 million and a near doubling of operating profit to €77.5 million. One feature of the year was the full integration of the Aptuit contract research organisation, acquired in 2017. Another was a new alliance with Celgene Corp in targeted protein degradation.
A new gene therapy has been given a favourable scientific review in Europe paving the way for its use in patients with beta-thalassaemia as early as the second quarter. The treatment, Zynteglo, uses a lentiviral vector to deliver functional copies of a beta-globin gene into a patient’s haematopoietic stem cells in order to correct for a shortage of beta-globin. It was given a positive opinion by the European Medicines Agency on 29 March.
Antibody-drug conjugates (ADCs) have assumed new prominence as cancer treatments in the wake of a deal between AstraZeneca Plc and Daiichi Sankyo Co Ltd of Japan to co-develop trastuzumab deruxtecan, an ADC for a group of HER2-mutated cancers.
AstraZeneca is to pay the Japanese company $1.35 billion initially for rights to the late-stage ADC candidate which received a ‘breakthrough therapy’ designation from the US Food and Drug Administration in 2017. The two companies expect to make a regulatory submission in the second half of this year.
A type of inflammatory arthritis that affects the spine but cannot be detected by x-ray now has an approved treatment. The US Food and Drug Administration has authorised Cimzia (certolizumab pegol) for the treatment of non-radiographic axial spondyloarthritis, a disease that starts in patients under the age of 45 years and can get progressively worse. The fact that the disorder cannot be identified by x-ray sets it apart from other inflammatory conditions in the same disease group.
Galapagos NV and Gilead Sciences Inc have announced positive data from two ongoing Phase 3 trials of the Janus kinase-1 (JAK1) inhibitor filgotinib in rheumatoid arthritis (RA). The trials, FINCH 1 and FINCH 3, met the primary and key secondary endpoints with favourable safety data at the 24 week cut-off date.
France-based Genfit SA has raised $135 million in a global share offering that includes a listing on the Nasdaq over-the-counter market in the US. The company’s US listing is in the form of American Depositary Shares (ADSs). The company has been trading on the Euronext exchange in Paris since 2006.
The global offering, which was priced on 27 March, consists of 6,650,000 new ordinary shares, of which 6,150,000 are in the form of Nasdaq-listed ADS at a price of $20.32 per ADS. The remaining 500,000 shares were placed in Europe and elsewhere at a price of €18 per share.
The US Food and Drug Administration has approved a new drug for the treatment of patients with multiple sclerosis (MS) whose disease gradually worsens over time leading to a disruption of brain function through inflammation and tissue loss. The drug, Mayzent (siponimod), is a small molecule indicated for active secondary progressive MS.
A prospective therapy for birch allergy failed to achieve the primary endpoint in a Phase 3 multi-center trial, according to the developer Allergy Therapeutics Plc. The therapy, B301, is a short-course treatment for birch-pollen induced seasonal allergic rhinitis.
It failed to show statistical significance relative to placebo. The safety and tolerability profile of the therapy were positive.